{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:11:16Z","timestamp":1792689076815,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Pediatric Orthopaedic Society of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jposna.2025.100262","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T15:53:18Z","timestamp":1757087598000},"page":"100262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Medication-Related Impacts on Pediatric Bone Health"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7868-2561","authenticated-orcid":false,"given":"Charu","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valdivia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena C.","family":"Ranade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib1","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1542\/peds.2014-2173","article-title":"Optimizing bone health in children and adolescents","volume":"134","author":"Golden","year":"2014","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1210\/clinem\/dgae507","article-title":"Approach to the pediatric patient with glucocorticoid-induced osteoporosis","volume":"110","author":"Ward","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jposna.2025.100262_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5435\/00124635-200708000-00002","article-title":"The effects of medications on bone","volume":"15","author":"Goodman","year":"2007","journal-title":"J Am Acad Orthop Surg"},{"key":"10.1016\/j.jposna.2025.100262_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/164_2019_340","article-title":"Drugs causing bone loss","volume":"262","author":"Vestergaard","year":"2020","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jposna.2025.100262_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fendo.2020.00603","article-title":"Hormonal contraception and bone health in adolescents","volume":"11","author":"Bachrach","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/MOP.0000000000001290","article-title":"Bone health in children undergoing solid organ transplantation","volume":"35","author":"Pinto","year":"2023","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jposna.2025.100262_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.839972","article-title":"A narrative review on efficacy and safety of proton pump inhibitors in children","volume":"13","author":"Dipasquale","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","article-title":"Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics","volume":"15","author":"Ward","year":"2013","journal-title":"Paediatr Drugs"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamapediatrics.2020.0007","article-title":"Association between proton pump inhibitor use and risk of fracture in children","volume":"174","author":"Wang","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jposna.2025.100262_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.lfs.2018.12.058","article-title":"Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis","volume":"218","author":"Liu","year":"2019","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib11","doi-asserted-by":"crossref","first-page":"e2071","DOI":"10.1210\/clinem\/dgae598","article-title":"Sex-specific association of chronic proton pump inhibitor use with reduced bone density and quality","volume":"110","author":"Bioletto","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.jposna.2025.100262_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810733","article-title":"Proton pump inhibitors and bone health: an update narrative review","volume":"23","author":"Lespessailles","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jposna.2025.100262_bib13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamapediatrics.2014.1273","article-title":"Efficacy and safety of histamine-2 receptor antagonists","volume":"168","author":"van der Pol","year":"2014","journal-title":"JAMA Pediatr"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2008.08.045","article-title":"American gastroenterological association medical position statement on the management of gastroesophageal reflux disease","volume":"135","author":"Kahrilas","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jposna.2025.100262_bib15","doi-asserted-by":"crossref","first-page":"712939","DOI":"10.3389\/fphar.2021.712939","article-title":"Acid-suppressive drugs and risk of fracture in children and young adults: a meta-analysis of observational studies","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/03007995.2022.2037847","article-title":"A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients","volume":"38","author":"Fleishman","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib17","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2625","article-title":"Early acid suppression therapy exposure and fracture in young children","volume":"144","author":"Malchodi","year":"2019","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.jposna.2025.100262_bib18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.pharep.2018.03.005","article-title":"Effect of long-term administration of ranitidine, a histamine H2 receptor antagonist, on bone metabolism in young growing rats","volume":"70","author":"Matuszewska","year":"2018","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pharep.2013.08.010","article-title":"Modifications of histamine receptor signaling affect bone mechanical properties in rats","volume":"66","author":"Folwarczna","year":"2014","journal-title":"Pharmacol Rep"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020444","article-title":"Clinical use and molecular action of corticosteroids in the pediatric age","volume":"20","author":"Ferrara","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"36","key":"10.1016\/j.jposna.2025.100262_bib21","doi-asserted-by":"crossref","first-page":"14616","DOI":"10.1073\/pnas.1309898110","article-title":"Glucocorticoid receptor represses proinflammatory genes at distinct steps of the transcription cycle","volume":"110","author":"Gupte","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jposna.2025.100262_bib22","series-title":"StatPearls","article-title":"Physiology, glucocorticoids","author":"Chourpiliadis","year":"2023"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jamapediatrics.2019.0834","article-title":"Glucocorticoids for croup in children","volume":"173","author":"Gates","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semarthrit.2019.03.010","article-title":"Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus","volume":"49","author":"Deng","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jposna.2025.100262_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cytogfr.2023.03.002","article-title":"Pathogenic mechanisms of glucocorticoid-induced osteoporosis","volume":"70","author":"Chen","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"issue":"8","key":"10.1016\/j.jposna.2025.100262_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.jposna.2025.100262_bib28","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/jbmr.3447","article-title":"Bone morbidity and recovery in children with acute lymphoblastic leukemia: results of a six-year prospective cohort study","volume":"33","author":"Ward","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.15844\/pedneurbriefs-21-6-2","article-title":"Outcome of long-term corticosteroid treatment in duchenne muscular dystrophy","volume":"21","author":"Millichap","year":"2007","journal-title":"Pediatr Neurol Briefs"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.semarthrit.2014.02.002","article-title":"A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children","volume":"44","author":"Hansen","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/MPG.0b013e31821988a3","article-title":"Skeletal health of children and adolescents with inflammatory bowel disease","volume":"53","author":"Pappa","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.7965","article-title":"Psychotropic medication prescribing for children and adolescents after the onset of the COVID-19 pandemic","volume":"7","author":"Valtuille","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jposna.2025.100262_bib33","series-title":"Trends in mental health care among children and adolescents","author":"Olfson","year":"2015"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib34","first-page":"81","article-title":"National trends in the mental health care of children, adolescents, and adults by office-based physicians","volume":"71","author":"Olfson","year":"2014","journal-title":"JAMA Psyc"},{"key":"10.1016\/j.jposna.2025.100262_bib35","first-page":"287","article-title":"Prescribing trends of antidepressants and psychotropic coprescription for youths in UK primary care, 2000-2018","author":"Cao","year":"2021","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jposna.2025.100262_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2022.09.007","article-title":"Rates of psychotropic medicine prescribing in paediatric populations in Australian general practice from 2000-2016","volume":"65","author":"Tanana","year":"2022","journal-title":"Europ Neuropsychopharmacol: J European College Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.jposna.2025.100262_bib37","first-page":"26","article-title":"Antidepressants for pediatric patients","volume":"18","author":"Dwyer","year":"2019","journal-title":"Current Psyc"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/s40272-013-0014-8","article-title":"The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis","volume":"15","author":"Lam","year":"2013","journal-title":"Paediatric Drugs"},{"issue":"7","key":"10.1016\/j.jposna.2025.100262_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003215","article-title":"Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: a population-based cohort study","volume":"17","author":"Jack","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jposna.2025.100262_bib40","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra2033475","article-title":"Depression in adolescents","author":"Miller","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1542\/peds.2014-1581","article-title":"Pediatric psychopharmacology for treatment of ADHD, depression, and anxiety","volume":"136","author":"Southammakosane","year":"2015","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2012.11.003","article-title":"Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function","volume":"74","author":"Hodge","year":"2013","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.jposna.2025.100262_bib43","doi-asserted-by":"crossref","DOI":"10.1359\/JBMR.040606","article-title":"Serotonin regulates osteoclast differentiation through its transporter","volume":"19","author":"Battaglino","year":"2004","journal-title":"J Bone Miner Res: Off J Am Soc Bone Mineral Res"},{"key":"10.1016\/j.jposna.2025.100262_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-66653-2_3","article-title":"Regulation of bone metabolism by serotonin","volume":"1033","author":"Lavoie","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40266-015-0323-4","article-title":"Effects of depression and serotonergic antidepressants on bone: mechanisms and implications for the treatment of depression","volume":"33","author":"Fernandes","year":"2015","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib46","doi-asserted-by":"crossref","DOI":"10.1210\/en.2004-1259","article-title":"Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth","volume":"146","author":"Warden","year":"2005","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib47","article-title":"Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies","volume":"8","author":"Warden","year":"2008","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"7","key":"10.1016\/j.jposna.2025.100262_bib48","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.15m09828","article-title":"Antidepressant exposure and risk of fracture among medicaid-covered youth","volume":"77","author":"Gracious","year":"2016","journal-title":"J Clin Psychiatr"},{"key":"10.1016\/j.jposna.2025.100262_bib49","series-title":"Osteoporosis International: Journal of Established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","article-title":"Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies","volume":"23","author":"Wu","year":"2012"},{"issue":"5","key":"10.1016\/j.jposna.2025.100262_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.1554","article-title":"Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis","volume":"27","author":"Eom","year":"2012","journal-title":"J Bone Miner Res: Off J Am Soc Bone Mineral Res"},{"issue":"10","key":"10.1016\/j.jposna.2025.100262_bib51","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-020-02893-1","article-title":"Alliance between selective serotonin reuptake inhibitors and fracture risk: an updated systematic review and meta-analysis","volume":"76","author":"Kumar","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jposna.2025.100262_bib52","unstructured":"DailyMed - OPIPZA- aripiprazole film, soluble. Accessed June 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b47ede68-8942-4432-af7e-57afc14b2ba4."},{"key":"10.1016\/j.jposna.2025.100262_bib53","unstructured":"DailyMed - ABILIFY- aripiprazole tablet. Accessed June 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6875b848-8b13-45f8-ada5-69ef8aece6b6."},{"key":"10.1016\/j.jposna.2025.100262_bib54","unstructured":"DailyMed - RISPERDAL- risperidone tablet. Accessed June 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=01859e07-1262-4cc6-b7ed-5a273cbf0c36."},{"key":"10.1016\/j.jposna.2025.100262_bib55","unstructured":"DailyMed - INVEGA- paliperidone tablet, extended release. Accessed June 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916."},{"key":"10.1016\/j.jposna.2025.100262_bib56","unstructured":"DailyMed - ZYPREXA- olanzapine tablet ZYPREXA ZYDIS- olanzapine tablet, orally disintegrating ZYPREXA INTRAMUSCULAR- olanzapine injection, powder, for solution. Accessed June 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341."},{"issue":"7","key":"10.1016\/j.jposna.2025.100262_bib57","doi-asserted-by":"crossref","DOI":"10.1377\/hlthaff.2022.01625","article-title":"Antipsychotic medication use in medicaid-insured children decreased substantially between 2008 and 2016","volume":"42","author":"Bushnell","year":"2023","journal-title":"Health Aff"},{"issue":"7","key":"10.1016\/j.jposna.2025.100262_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2020.09.023","article-title":"Trends in antipsychotic medication use in young privately insured children","volume":"60","author":"Bushnell","year":"2021","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"issue":"9","key":"10.1016\/j.jposna.2025.100262_bib59","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"20","key":"10.1016\/j.jposna.2025.100262_bib60","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"64","author":"Haddad","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jposna.2025.100262_bib61","doi-asserted-by":"crossref","DOI":"10.1186\/1687-9856-2010-159402","article-title":"Hyperprolactinemia with antipsychotic drugs in children and adolescents","volume":"2010","author":"Rosenbloom","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib62","first-page":"197","article-title":"Prolactinoma in children and adolescents","volume":"72","author":"Fideleff","year":"2009","journal-title":"Horm Res"},{"issue":"3","key":"10.1016\/j.jposna.2025.100262_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s11126-005-2982-5","article-title":"Review of benzodiazepine use in children and adolescents","volume":"76","author":"Witek","year":"2005","journal-title":"Psychiatr Q"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib64","doi-asserted-by":"crossref","first-page":"16m11415","DOI":"10.4088\/JCP.16m11415","article-title":"Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications","volume":"79","author":"Bushnell","year":"2018","journal-title":"J Clin Psychiatr"},{"issue":"7","key":"10.1016\/j.jposna.2025.100262_bib65","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.sleep.2009.11.015","article-title":"Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey","volume":"11","year":"2010","journal-title":"Sleep Med"},{"issue":"8","key":"10.1016\/j.jposna.2025.100262_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002635","article-title":"Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study","volume":"15","author":"Sidorchuk","year":"2018","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.jposna.2025.100262_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/da.22643","article-title":"The efficacy of benzodiazepines as acute anxiolytics in children: a meta-analysis","volume":"34","author":"Kuang","year":"2017","journal-title":"Depress Anxiety"},{"issue":"3","key":"10.1016\/j.jposna.2025.100262_bib68","article-title":"Advances in pharmacotherapy for pediatric anxiety disorders","volume":"32","author":"Nicotra","year":"2023","journal-title":"Child Adoles Psychiat Clinic North America"},{"issue":"8","key":"10.1016\/j.jposna.2025.100262_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081242","article-title":"The impact of anti-epileptic drugs on growth and bone metabolism","volume":"17","author":"Fan","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jposna.2025.100262_bib70","series-title":"Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","article-title":"Association between use of benzodiazepines and risk of fractures: a meta-analysis","volume":"25","author":"Xing","year":"2014"},{"key":"10.1016\/j.jposna.2025.100262_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2023.101866","article-title":"Sedative-hypnotics and osteoporotic fractures: a systematic review of observational studies with over six million individuals","volume":"73","author":"Xu","year":"2024","journal-title":"Sleep Med Rev"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib72","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3478","article-title":"Benzodiazepine treatment and fracture risk in young persons with anxiety disorders","volume":"146","author":"Bushnell","year":"2020","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1099-1557(199701)6:1<27::AID-PDS240>3.0.CO;2-S","article-title":"A prospective study of falls after benzodiazepine use: a comparison of new and repeat use","volume":"6","author":"Maxwell","year":"1997","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/25.4.273","article-title":"New evidence on benzodiazepine use and falls: the time factor","volume":"25","author":"Neutel","year":"1996","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/1060028016682530","article-title":"Benzodiazepine initiation and dose escalation","volume":"51","author":"Skinner","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.jposna.2025.100262_bib76","doi-asserted-by":"crossref","DOI":"10.1089\/cap.2017.0077","article-title":"National patterns of commonly prescribed psychotropic medications to young people","volume":"28","author":"Sultan","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib77","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-2528","article-title":"Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-Deficit\/Hyperactivity disorder in children and adolescents","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.jposna.2025.100262_bib78","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2016.2804","article-title":"Association of stimulant medication use with bone mass in children and adolescents with attention-Deficit\/Hyperactivity disorder","volume":"170","author":"Feuer","year":"2016","journal-title":"JAMA Pediatr"},{"issue":"5","key":"10.1016\/j.jposna.2025.100262_bib79","doi-asserted-by":"crossref","DOI":"10.1097\/BPO.0000000000000651","article-title":"Preliminary evidence of an association between ADHD medications and diminished bone health in children and adolescents","volume":"37","author":"Howard","year":"2017","journal-title":"J Pediat Orthoped"},{"key":"10.1016\/j.jposna.2025.100262_bib80","article-title":"Influence of psychostimulants on bone mineral density and content among children with attention deficit hyperactivity disorder","volume":"179","author":"Burns","year":"2024","journal-title":"System Rev Bone"},{"key":"10.1016\/j.jposna.2025.100262_bib81","first-page":"120","article-title":"Lower risk of stress fractures in young adults with ADHD under chronic treatment with methylphenidate","author":"Schermann","year":"2019","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.jposna.2025.100262_bib82","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1111\/bcp.15714","article-title":"Treatment with methylphenidate and the risk of fractures among children and young people: a systematic review and self-controlled case series study","volume":"89","author":"Gao","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jposna.2025.100262_bib83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions - principles and clinical implications","volume":"8","author":"Johannessen","year":"2010","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jposna.2025.100262_bib84","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.yebeh.2003.11.025","article-title":"Bone health in pediatric epilepsy","volume":"5","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.jposna.2025.100262_bib85","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X11410769","article-title":"Antiepileptics and bone health","author":"Meier","year":"2011","journal-title":"Therap Adv Musculoskeletal Disease"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3476(95)70304-7","article-title":"Effect of carbamazepine and valproate on bone mineral density","volume":"127","author":"Sheth","year":"1995","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib87","doi-asserted-by":"crossref","DOI":"10.1007\/s40272-014-0115-z","article-title":"Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy","volume":"17","author":"Vestergaard","year":"2015","journal-title":"Paediatric Drugs"},{"key":"10.1016\/j.jposna.2025.100262_bib88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.seizure.2017.03.013","article-title":"The effect of VPA on bone: from clinical studies to cell cultures\u2014The molecular mechanisms revisited","volume":"48","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.jposna.2025.100262_bib89","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41392-023-01726-8","article-title":"Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss","volume":"9","author":"Xie","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.jposna.2025.100262_bib90","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bone.2019.01.003","article-title":"Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review","volume":"121","author":"Nasomyont","year":"2019","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib91","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40272-021-00487-7","article-title":"Drug treatment of low bone mass and other bone conditions in pediatric patients","volume":"24","author":"Costi","year":"2022","journal-title":"Paediatr Drugs"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib92","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2008-1531","article-title":"Clinical review 1: bisphosphonate use in childhood osteoporosis","volume":"94","author":"Bachrach","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib93","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40265-017-0715-3","article-title":"Pediatric osteoporosis: diagnosis and treatment considerations","volume":"77","author":"Marrani","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jposna.2025.100262_bib94","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/archdischild-2016-311820","article-title":"Bone protective agents in children","volume":"103","author":"Wood","year":"2018","journal-title":"Arch Dis Child"},{"issue":"7","key":"10.1016\/j.jposna.2025.100262_bib95","article-title":"Bisphosphonate use in children with cerebral palsy","volume":"7","author":"Hurley","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jposna.2025.100262_bib96","doi-asserted-by":"crossref","unstructured":"Noritz G, Davidson L, Steingass K, Council on Children with Disabilities, The American academy for cerebral palsy and developmental medicine, council on children with disabilities, the American academy for cerebral palsy and developmental medicine. Providing a primary care medical home for children and youth with cerebral palsy. Pediatrics. Published online November 21, 2022. doi:10.1542\/peds.2022-060055.","DOI":"10.1542\/peds.2022-060056"},{"issue":"9","key":"10.1016\/j.jposna.2025.100262_bib97","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib98","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib99","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"16","key":"10.1016\/j.jposna.2025.100262_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13164951","article-title":"Osteoporosis and bone fragility in children: diagnostic and treatment strategies","volume":"13","author":"Cannalire","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib101","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.intimp.2012.03.019","article-title":"Impact of tacrolimus on bone metabolism after kidney transplantation","volume":"13","author":"Luo","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib102","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1046\/j.1523-1755.2000.00341.x","article-title":"Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation","volume":"58","author":"Westeel","year":"2000","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.jposna.2025.100262_bib103","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bone.2007.07.021","article-title":"Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects","volume":"41","author":"Xian","year":"2007","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib104","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bone.2008.09.014","article-title":"Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment","volume":"44","author":"Fan","year":"2009","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.jposna.2025.100262_bib105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jor.24819","article-title":"Evaluation of impaired growth plate development of long bones in skeletally immature mice by antirheumatic agents","volume":"39","author":"Caron","year":"2021","journal-title":"J Orthop Res"},{"issue":"9","key":"10.1016\/j.jposna.2025.100262_bib106","first-page":"3121","article-title":"Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia","volume":"83","author":"Crofton","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jposna.2025.100262_bib107","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1053\/ctrv.2000.0180","article-title":"The effect of chemotherapy on the growing skeleton","volume":"26","author":"van Leeuwen","year":"2000","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib108","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajpath.2012.03.037","article-title":"Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-\u03baB activation","volume":"181","author":"King","year":"2012","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib109","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1677\/joe.0.1570225","article-title":"Chemotherapeutic agents used in the treatment of childhood malignancies have direct effects on growth plate chondrocyte proliferation","volume":"157","author":"Robson","year":"1998","journal-title":"J Endocrinol"},{"issue":"10","key":"10.1016\/j.jposna.2025.100262_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046915","article-title":"Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate","volume":"7","author":"Fan","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jposna.2025.100262_bib111","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.thromres.2006.10.025","article-title":"The effects of heparin and low molecular weight heparins on bone","volume":"122","author":"Rajgopal","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.jposna.2025.100262_bib112","doi-asserted-by":"crossref","first-page":"1192670","DOI":"10.3389\/fendo.2023.1192670","article-title":"Evaluation of bone mineral density and bone turnover in children on anticoagulation","volume":"14","author":"Thom","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jposna.2025.100262_bib113","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.blre.2018.06.003","article-title":"Are low-molecular-weight heparins safe and effective in children? A systematic review","volume":"33","author":"Klaassen","year":"2019","journal-title":"Blood Rev"},{"issue":"2 Suppl","key":"10.1016\/j.jposna.2025.100262_bib114","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jposna.2025.100262_bib115","doi-asserted-by":"crossref","first-page":"968485","DOI":"10.3389\/fped.2022.968485","article-title":"Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States","volume":"10","author":"Popovic","year":"2022","journal-title":"Front Pediatr"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib116","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.fertnstert.2007.10.070","article-title":"Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study","volume":"90","author":"Cromer","year":"2008","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib117","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.contraception.2007.10.005","article-title":"Bone density recovery after depot medroxyprogesterone acetate injectable contraception use","volume":"77","author":"Kaunitz","year":"2008","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.jposna.2025.100262_bib118","first-page":"331","article-title":"Removing barriers to contraceptive access for adolescents","volume":"29","author":"Reilly","year":"2024","journal-title":"J Pediatr Pharmacol Therapeut"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib119","first-page":"104","article-title":"An examination of the effects of leuprolide acetate used in the treatment of central precocious puberty on bone mineral density and 25-hydroxy vitamin D","volume":"64","author":"Kaya","year":"2015","journal-title":"West Indian Med J"},{"issue":"11","key":"10.1016\/j.jposna.2025.100262_bib120","first-page":"3951","article-title":"Clinical review 117: hormonal determinants and disorders of peak bone mass in children","volume":"85","author":"Soyka","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib121","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00223-022-00955-3","article-title":"Role of vitamin K in bone and muscle metabolism","volume":"112","author":"Alonso","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib122","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1017\/S0007114508921760","article-title":"Vitamin K status is associated with childhood bone mineral content","volume":"100","author":"van Summeren","year":"2008","journal-title":"Br J Nutr"},{"issue":"5","key":"10.1016\/j.jposna.2025.100262_bib123","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/07315724.2017.1307791","article-title":"Roles of vitamins D and K, nutrition, and lifestyle in low-energy bone fractures in children and young adults","volume":"36","author":"Karpi\u0144ski","year":"2017","journal-title":"J Am Coll Nutr"},{"issue":"10","key":"10.1016\/j.jposna.2025.100262_bib124","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0899-9007(01)00709-2","article-title":"Vitamin K and bone health","volume":"17","author":"Weber","year":"2001","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/000992289503400202","article-title":"Rickets secondary to phosphate depletion. A sequela of antacid use in infancy","volume":"34","author":"Pivnick","year":"1995","journal-title":"Clin Pediatr (Phila)"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib126","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1345\/aph.1D271","article-title":"Metabolic bone disease after chronic antacid administration in an infant","volume":"38","author":"Robinson","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib127","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/archdischild-2023-325802","article-title":"Association of early-life exposure to acid-suppressive therapy and fractures during childhood: a retrospective cohort study","volume":"109","author":"Achler","year":"2023","journal-title":"Arch Dis Child"},{"issue":"6","key":"10.1016\/j.jposna.2025.100262_bib128","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1210\/er.2012-1071","article-title":"Vitamin a metabolism, action, and role in skeletal homeostasis","volume":"34","author":"Conaway","year":"2013","journal-title":"Endocr Rev"},{"issue":"21","key":"10.1016\/j.jposna.2025.100262_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/nu14214694","article-title":"Vitamin A nutritional status is a key determinant of bone mass in children","volume":"14","author":"Zhang","year":"2022","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib130","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1096\/fj.201802040R","article-title":"Vitamin A decreases the anabolic bone response to mechanical loading by suppressing bone formation","volume":"33","author":"Lionikaite","year":"2019","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.jposna.2025.100262_bib131","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/ajcn\/nqab422","article-title":"Chronic and acute hypervitaminosis A are associated with suboptimal anthropometric measurements in a cohort of South African preschool children","volume":"115","author":"Sheftel","year":"2022","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.jposna.2025.100262_bib132","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jposna.2025.100262_bib133","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1210\/clinem\/dgae290","article-title":"Vitamin D for the prevention of disease: an endocrine society clinical practice guideline","volume":"109","author":"Demay","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jposna.2025.100262_bib134","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.annepidem.2007.12.001","article-title":"Vitamin D status: measurement, interpretation, and clinical application","volume":"19","author":"Holick","year":"2009","journal-title":"Ann Epidemiol"},{"issue":"11","key":"10.1016\/j.jposna.2025.100262_bib135","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1249\/01.MSS.0000142662.21767.58","article-title":"American College of Sports Medicine Position Stand: physical activity and bone health","volume":"36","author":"Kohrt","year":"2004","journal-title":"Med Sci Sports Exerc"},{"issue":"14","key":"10.1016\/j.jposna.2025.100262_bib136","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1091\/mbc.e17-02-0084","article-title":"Mechanical loading regulates organization of the actin cytoskeleton and column formation in postnatal growth plate","volume":"28","author":"Killion","year":"2017","journal-title":"Mol Biol Cell"}],"container-title":["Journal of the Pediatric Orthopaedic Society of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2768276525001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2768276525001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T10:14:45Z","timestamp":1762856085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2768276525001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":136,"alternative-id":["S2768276525001063"],"URL":"https:\/\/doi.org\/10.1016\/j.jposna.2025.100262","relation":{},"ISSN":["2768-2765"],"issn-type":[{"value":"2768-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-Related Impacts on Pediatric Bone Health","name":"articletitle","label":"Article Title"},{"value":"Journal of the Pediatric Orthopaedic Society of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jposna.2025.100262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Pediatric Orthopaedic Society of North America.","name":"copyright","label":"Copyright"}],"article-number":"100262"}}